Is Lisuride safe while breastfeeding?
Here is what LactMed, the Drugs and Lactation Database published by the U.S. National Institute of Child Health and Human Development (NICHD), reports about Lisuride. The text below is quoted from that source — it is not our own verdict.
Summary of use during breastfeeding
Lisuride is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. It lowers serum prolactin and is approved in some countries for lactation suppression. Some experts recommend lisuride as a safer alternative to bromocriptine for lactation suppression, but others recommend avoiding all lactation suppressants.[1,2] Data are insufficient recommend one treatment for lactation suppression over another.[3]
Effects on the breastfed infant
Relevant published information was not found as of the revision date.
Effects on milk supply
Lisuride suppresses serum prolactin increases in a dose-related fashion.[4,5] Comparative studies have found lisuride comparable in efficacy to bromocriptine, although rebound lactation occurred in more patients treated with lisuride 0.4 mg daily than in those treated with bromocriptine 5 mg daily.[6,7] Rebound lactation appears to be less with a higher dose of 0.6 mg daily and with 15 days of therapy rather than 10 days.[8,9]
Levels in milk
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Alternatives LactMed lists
Source: Drugs and Lactation Database (LactMed), National Institute of Child Health and Human Development (NICHD), via NCBI Bookshelf, record “Lisuride” (LM1224). LactMed on NCBI Bookshelf. LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.